Biodexa Pharmaceuticals Plc
BDRX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001643918
No open-market purchases or sales by Biodexa Pharmaceuticals Plc insiders were filed in the last 90 days; 8 institutions reported holding it in 13F filings for Q2 2026, worth $48.1K in total; no superinvestor holds it.
Q3 2024 vs. Q2 2024
How the institutions holding Biodexa Pharmaceuticals Plc changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Q3 2024 | Change |
|---|---|---|---|
| Holders | 12 | 7 | −5 |
| Shares | 151.4K | 309.7K | +158.3K (+104.5%) |
| Value | $135.6K | $87.3K | −$48.3K (−35.6%) |
New holders (1)
Institutions that held Biodexa Pharmaceuticals Plc at the end of Q3 2024 but not at the end of Q2 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Hantz Financial Services, Inc. | 30 | $0 | 0.00% |
Sold out (6)
Institutions that held Biodexa Pharmaceuticals Plc at the end of Q2 2024 and filed for Q3 2024 without it.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| Virtu Financial LLC | 35,776 | $32.0K |
| Citadel Advisors LLC | 33,441 | $30.0K |
| Susquehanna International Group, LLP | 30,114 | $27.0K |
| Ground Swell Capital, LLC | 13,078 | $11.7K |
| Bank of America Corp | 859 | $769 |
| Headlands Technologies LLC | 8 | $7 |